National, July 9, 2025: Anthem Biosciences Limited (the “Company”) proposes to open an initial public offering(“Offer”) of its equity shares of face value of ₹2 each (“Equity Shares”) on Monday, July 14, 2025. The Anchor Investor Bidding Date is one Working Day prior to Bid/Offer Opening Date, being Friday, July 11, 2025. The Bid/ Offer Closing Date is Wednesday, July 16, 2025.
The Price Band of the Offer has been fixed from ₹ 540 perEquity Share to ₹ 570 per Equity Share. Bids can be made for a minimum of 26 Equity Shares and multiples of 26 Equity Shares thereafter.
The Initial Public Offering comprises an Offer for Sale of Equity Shares aggregating up ₹33,950 million by the Selling Shareholders comprising of Equity Shares aggregating up to ₹3,500 million by Ganesh Sambasivam; Equity Shares aggregating up to ₹3,500 million by K Ravindra Chandrappa; Equity Shares aggregating up to ₹ 13,250 million by Viridity Tone LLP; Equity Shares aggregating up to ₹ 3,200 million each by Portsmouth Technologies LLC, Malay J Barua, Rupesh N Kinekar and Satish Sharma; Equity Shares aggregating up to ₹ 800 million by Prakash Kariabettan and Equity Shares aggregating up to ₹ 100 million by K Ramakrishnan.
The Offer includes a reservation of Equity Shares of face value of ₹2 each, aggregating up to ₹ 82.50 million for subscription by Eligible Employees (the “Employee Reservation Portion”). The Offer less the Employee Reservation Portion is hereinafter referred to as the “Net Offer”. A discount of ₹50 per Equity Share is being offered to Eligible Employees bidding in the Employee Reservation Portion (“Employee Discount”).
The Offer is being made in terms of Rule 19(2)(b) of the SCRR, read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that our Company in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors and the basis of such allocation will be on a discretionary basis by our Company, in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations (the “Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors (“Anchor Investor Allocation Price”). In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the “Net QIB Portion”).
Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Offer Price.
Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Investors (“Non-Institutional Portion”) of which one-third of the Non-Institutional Portion shall be available for allocation to Bidders with an application size of more than ₹ 0.20 million and up to ₹ 1.00 million and two-thirds of the Non-Institutional Portion shall be available for allocation to Bidders with an application size of more than ₹ 1.00 million and undersubscription in either of these two sub-categories of the Non-Institutional Portion may be allocated to Bidders in the other sub-category of the Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price.
Further, not less than 35% of the Offer shall be available for allocation to Retail Individual Investors (“Retail Portion”), in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price.
Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid bids received from them at or above the Offer Price.
All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount (“ASBA”) process and shall provide details of their respective bank account (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) in which the Bid Amount will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or pursuant to the UPI Mechanism, as the case may be. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process.
The Equity Shares of the Company are proposed to be listed on BSE Limited (“BSE“) and the National Stock Exchange of India Limited (“NSE”) (BSE and NSE together, the “Stock Exchanges”). JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the Book Running Lead Managers (“BRLMs”) to the Offer.
Disclaimer:
Anthem Biosciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with RoC and the Stock Exchanges on July 8, 2025. The RHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.anthembio.com; and on the websites of the BRLMs, i.e. JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.jmfl.com, https://www.citigroup.com/global/about-us/global-presence/india/disclaimer, www.jpmipl.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively.
Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see ‘Risk Factors’ on page 34 of the RHP filed with SEBI and the Stock Exchanges, when filed. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, for making investment decision.
This announcement is not an offer of securities for sale in the United States or elsewhere. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Anthem Biosciences Limited does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States.